Manitoba adults with spinal muscular atrophy gain continued access to risdiplam
Jeremy Bray, 31, of Rivers, Man., who has Type 2 spinal muscular atrophy, will keep access to risdiplam (Evrysdi) after Canada's Drug Agency issued a draft recommendation supporting expanded public coverage for the drug in adults over 25, reversing its earlier position. Manitoba Health Minister Uzoma Asagwara told Bray the province will follow the updated recommendation, saying 'Jeremy is covered.' The drug costs roughly $300,000 a year; the recommendations are not binding and negotiations with the manufacturer are still required.
A federal reversal on age limits for a high-cost rare-disease drug, followed by a provincial coverage promise, could open access for other Manitoba adults over 25 with spinal muscular atrophy — and ends years of uncertainty for a patient whose treatment was about to stop.
Ask about this brief
Answers are written by AI from this brief and can be wrong. Check the original source before you act.
2 free questions a day without an account. Members ask as often as they like, free.
Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.
Read the original
News source: Manitoba adults with spinal muscular atrophy gain continued access to risdiplam (opens in a new tab) — CBC News

